Because this project lost its foundation funding on July 1, 2013, the publisher is unable to pay any of the terrific reviewers pictured at upper right on this page. We hope this is only a temporary situation as we continue to pursue other funding sources. Meantime, the publisher will continue to write frequently on the Health News Watchdog blog on this site.
Thank you for your continued interest.
It’s difficult to do an overview of melanoma drug research in a relatively brief story. But this story did a solid job.
An adequate summary of this asthma drug trial’s design doesn’t make up for the overly optimistic tone about the drug’s future. A New York Times story was better.
This story focuses on a family that may have a rare genetic mutation that increases their risk of heart disease. Unfortunately, the “rare” part wasn’t mentioned until 1,600 words into this 2,100 word story.
While this story adequately addressed 7 of our 10 criteria, the 3 on which it missed were significant omissions, yet could have been easily addressed.
Solid medical conference reporting, with many expert interviews and good context provided. Goes far beyond the conference presentation itself.
Overall, a fairly thorough report that addressed almost all of our criteria satisfactorily.
If you skim too quickly, you’ll miss that this “breakthrough” in type 2 diabetes research came from a study of mice — not humans. The story may have overstated the promise of bench research.
This story addressed most of our criteria. The ones it missed could have been easily addressed.